SLDB

Solid Biosciences Inc.

6.70 USD
+0.24 (+3.72%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Solid Biosciences Inc. stock is down -13.99% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 June’s closed higher than May. 67% of analysts rate it a buy.

About Solid Biosciences Inc.

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles.

  • Leerink Partners
    Mon Jun 24, 07:10
    buy
    upgrade
  • Piper Sandler
    Fri Jun 21, 13:48
    buy
    confirm
  • JP Morgan
    Fri May 31, 13:17
    hold
    confirm